PRFX (painreform.com) Company Projected Revenue

PRFX (PainReform Corp) - company brandmark

The market value of PainReform Ltd. (PRFX) already prices in liquidity shortages and small-cap biotech risks. This chart of the company's future trading volume, sourced from the GURU.Markets terminal, identifies 0.00 as the current benchmark. Patents for the Plex03 technology ensure business stability, while management's lean approach to research aims to confirm the efficacy of pain management systems under strict FDA oversight.

PRFX - PainReform Corp Projected Sales Volume over the range 07/04/2022 - 11/13/2026

PainReform Ltd (PRFX) - metric breakdowns and financial figures

- stock value and consensus price forecast:
Price Chart PainReform Ltd.|PRFX - Fair Value Consensus
- business market valuation indicators:
Market Value PainReform Ltd|PRFX - Full Business Value
- balance sheet equity data:
Book Value per Share PainReform|PRFX - Book Capitalization|Market Capitalization to Book Value Ratio painreform.com|PRFX - Company Total Asset Base
- company total debt and liquidity indicators:
Debt to Equity PainReform Ltd.|PRFX - Long-Term Debt to Capital Ratio|Short-Term Debt to Equity PainReform Limited|PRFX - Aggregate Debt Obligations|Debts to Book Capitalization PainReform Ltd|PRFX - Long-Term Debt|Company Short-Term Debts PainReform|Quick Liquidity painreform.com
- earnings and market ratios statistics:
PRFX - Company Net Income|Expected Profit PainReform Ltd.|PRFX - Company Value to Net Income|Future Price to Earnings PainReform|PRFX - Price/Earnings to Growth Multiple|Enterprise Value to EBITDA Ratio PainReform Ltd|PRFX - Income before deduction of interest, taxes and amortization|Earnings per share for the last twelve months PainReform|PRFX - Earnings per share for the last twelve months|Year-over-year net earnings per share growth for the last 12 months painreform.com|PRFX - Net earnings per one share growth for the current year|Earnings growth forecast for next year PainReform Ltd.
- sales volume and revenue indicators:
PRFX - Company Sales Volume|Company Future Sales Volume PainReform Ltd.|PRFX - Price-to-Revenue Coefficient|Price-to-Projected Revenue Ratio PainReform Ltd
Fundamental valuation:PainReform Ltd.
Signature product of PainReform Limited

Professional capital evaluates the profile of PainReform Ltd. (PRFX) through the lens of sustainable revenue growth. This indicator filters out market noise, revealing the long-term trajectory of product implementation. By analyzing the dynamics of the company's prospective sales, investors see the expansion potential of the PRF-110 platform into surgical protocols. High switching costs for clinics ensure the stability of this trend. The positive slope of the curve confirms the fundamental reliability of the asset.

Competitors of PainReform Ltd. (PRFX)

Company Projected Revenue Haleon plc (HLN)|KVUE (kenvue.com) - Company Future Revenue|Company Projected Revenue Verona Pharma VRNA|MENS (Jyong Biotech Limited) - Company Expected Revenue|Ligand Pharma - Projected Sales Volume|AMRX - Projected Sales Volume|PRGO: Projected Sales Volume|ALVO - Company Future Sales|Company Projected Revenue Liquidia|Company Revenue Forecast GLPG (Galapagos N.V.)|Company Projected Revenue ANI Pharma (ANIP)|MNKD (Afrezza) - Company Future Revenue|Projected Sales Volume AMPH (Amphastar Pharmaceuticals)|pacira.com (PCRX) - Company Expected Sales Volume|ARS Pharmaceuticals, Inc. - Projected Sales Volume|Company Expected Revenue TBPH|Aquestive Pharma (AQST) - Company Projected Revenue|Company Expected Sales Volume scPharmaceuticals (SCPH)|Company Projected Revenue Tectonic Therapeutic Inc.|TNXP: Company Future Revenue|Company Projected Revenue China SXT Pharmaceuticals (SXTC)|Company Future Sales Volume eupraxiapharma.com EPRX|BioHarvest - Company Future Sales Volume|Company Future Revenue EXOZ|ORMP - Company Projected Revenue|ENTX: Company Projected Revenue|HYFT (MindWalk Holdings Inc.) - Company Future Sales Volume|ABVC: Company Projected Revenue Volume|CPIX (Cumberland Pharma) - Projected Sales Volume|Company Revenue Forecast QNTM (Quantum BioPharma Corp)|Company Future Sales Volume FGEN (FibroGen, Inc.)|Company Future Sales telomirpharma.com|Company Projected Revenue Rani Therapeutics Holdings, Inc. RANI|SNYR (Synergy CHC Corp.) - Company Expected Revenue|RLYB - Company Projected Revenue|Company Future Revenue LEXX (Lexaria Bioscience)|PULM: Projected Sales Volume|Company Expected Revenue PTHL (Pheton Holdings)|Company Future Sales Volume APM|Company Revenue Forecast LYRA (Lyra Therapeutics Inc.)|Company Projected Revenue Impact BioMedical (IBO)|TNFA: Company Expected Revenue|Projected Sales Volume YCBD (cbdMD)|Company Future Revenue CYTO|Lipella Pharmaceuticals, Inc. - Projected Sales Volume|OPTN - Projected Sales Volume|Pieris (PIRS) - Company Projected Revenue|Procaps Group Corp - Company Future Revenue|Company Projected Revenue Petros Pharmaceuticals|Company Future Sales Volume qlsyy.net (QLI)|Projected Sales Volume SLRN|Projected Sales Volume TFF Pharmaceuticals Inc. (TFFP)